Journals / Ankara Medical Journal / 2021 / Cilt: 21 - Sayı: 4

NONTHYROIDAL ILLNESS SYNDROME

NONTİROİDAL HASTALIK SENDROMU

Pages
687–700
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In many studies, routine thyroid hormone replacement is not recommended, as it does not give a positive or negative net result.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the pathophysiology of thyroid hormone changes observed in acute or chronic diseases is not clearly understood, it has been known for about the last 50 years that the body has an adaptive metabolic response.
📊
Key Findings & Data:The most known of this thyroid hormone change pattern, defined as a non-thyroid disease, are low triiodothyronine (T3) and increased reverse T3 (rT3) levels.
💡
Conclusion & Impact:In many studies, routine thyroid hormone replacement is not recommended, as it does not give a positive or negative net result.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although the pathophysiology of thyroid hormone changes observed in acute or chronic diseases is not clearly understood, it has been known for about the last 50 years that the body has an adaptive metabolic response. On the other hand, it has also been shown in many studies that it can make inferences about the prognosis of the primary underlying disease. The most known of this thyroid hormone change pattern, defined as a non-thyroid disease, are low triiodothyronine (T3) and increased reverse T3 (rT3) levels. Although many pathogenetic mechanisms are thought to lead to these changes, the most known are changes in deiodinase activity, thyrotropin (TSH) secretion, and serum carrier proteins and/or cellular carrier receptors. Changes in thyroid hormones can vary at different stages of the primary underlying disease. In addition, in different clinical conditions or pathologies, thyroid hormones are affected in different ways, causing difficulty in the differential diagnosis. Many drugs used in the clinic are also known to affect thyroid hormones at different levels and directions. Current conditions should be taken into account when evaluating, and if possible, a full panel of thyroid hormones, especially TSH with free thyroxine (sT4), should be seen. The need for treatment should be decided by taking into account laboratory findings as well as the patient's clinical presentation and history. In many studies, routine thyroid hormone replacement is not recommended, as it does not give a positive or negative net result.

Özet

Akut veya kronik hastalıklarda görülen tiroid hormon değişimlerinin her ne kadar patofizyolojisi net anlaşılmasa da vücudun metabolik olarak verdiği adaptif cevap olduğu yaklaşık son 50 yıldır bilinmektedir. Öte yandan primer altta yatan hastalığın prognozu ile ilgili çıkarımlar yaptırabileceği de birçok çalışmada gösterilmiştir. Nontiroidal hastalık olarak tanımlanan bu tiroid hormon değişim paterninin en bilinenleri düşük triiyodotironin (T3) ve artmış revers T3 (rT3) seviyeleridir. Birçok patogenetik mekanizmanın bu değişimlere yol açtığı düşünülse de en bilinenleri deiyodinaz aktivitesindeki, tirotropin (TSH) salgılanmasındaki ve serum taşıyıcı proteinlerinde ve/veya hücresel taşıyıcı reseptörlerindeki değişikliklerdir. Tiroid hormonlarındaki değişimler primer altta yatan hastalığın farklı evrelerinde değişkenlik gösterebilir. Ayrıca farklı klinik durum ya da patolojilerde tiroid hormonları farklı şekillerde etkilenerek ayırıcı tanı güçlüğüne neden olabilir. Klinikte kullanılan birçok ilacın da tiroid hormonlarını farklı düzeylerde ve yönlerde etkilediği bilinmektedir. Değerlendirme yapılırken mevcut durumlar göz önünde bulundurulmalı ve mümkünse serbest tiroksin (sT4) ile TSH başta olmak üzere tam tiroid hormon paneli görülmelidir. Tedavi gerekliliğine, laboratuvar bulguları yanında hastanın klinik prezentasyonu ve öyküsü de dikkate alınarak karar verilmelidir. Yapılan çok sayıda çalışmada rutin tiroid hormon replasmanı, olumlu veya olumsuz yönde net sonuç vermediğinden önerilmemektedir.

🔖

Cite This Article

ÇAKIR, B., BAŞER, H., DURMUŞ, B. (2022). NONTHYROIDAL ILLNESS SYNDROME. Ankara Medical Journal, Cilt: 21 - Sayı: 4, 687–700. https://ajindex.com/articles/441737

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lee S, Farwell AP. Euthyroid Sick Syndrome. Comprehensive Physiology. 2016;6(2):1071-80 (doi:10.1002/cphy.c150017)
  2. Fliers E, Bianco A, Langouche L, Boelen A. Endocrine and metabolic considerations in critically ill patients 4. Lancet Diabetes Endocrinol. 2015;3(10):816-25
  3. Farwell AP. Nonthyroidal illness syndrome. Current Opinion in Endocrinology, Diabetes and Obesity. 2013;20(5):478-84. 4. de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal illness syndrome. J Endocrinol. 2015;225(3):R67-81
  4. Pappa TA, Vagenakis AG, Alevizaki M. The nonthyroidal illness syndrome in the non–critically ill patient. European journal of clinical investigation. 2011;41(2):212-20
  5. Mebis L, Van den Berghe G. The hypothalamus-pituitary-thyroid axis in critical illness. Neth J Med. 2009;67(10):332-40
  6. Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: An update. The Journal of endocrinology. 2009;205(1):1-13
  7. Mebis L, Paletta D, Debaveye Y, et al. Expression of thyroid hormone transporters during critical illness. European journal of endocrinology. 2009;161(2):243
  8. Chopra IJ. Euthyroid sick syndrome: is it a misnomer? The Journal of Clinical Endocrinology & Metabolism. 1997;82(2):329-34
  9. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3, 3′, 5′-triiodothyronine (rT3) and 3, 5, 3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. The Journal of Clinical Endocrinology & Metabolism. 2005;90(8):4559-65
  10. De Groot LJ. Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. Critical care clinics. 2006;22(1):57-86
  11. Langouche L, Jacobs A, Van den Berghe G. Nonthyroidal illness syndrome across the ages. Journal of the Endocrine Society. 2019;3(12):2313-25
  12. Fekete C, Lechan RM. Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal afferents and type 2 deiodinase. Frontiers in neuroendocrinology. 2007;28(2-3):97-114
  13. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocrine reviews. 2011;32(5):670-93
  14. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression i